Inhaled Corticosteroids
The preventer inhaler — the one that saves lives, and the one people skip
In asthma, inhaled corticosteroids reduce exacerbations, hospitalisations and mortality, and confidence in this is high. Reliever-only (short-acting beta-agonist) treatment is no longer recommended even in mild asthma, because it is associated with severe exacerbations and death — a genuine reversal of decades of practice. In COPD the indication is much narrower: inhaled steroids benefit patients who continue to exacerbate despite bronchodilators, particularly those with higher blood eosinophil counts, and they increase pneumonia risk. Local side effects are common and preventable; systemic effects are real but dose-dependent and small at standard doses.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
High confidence
In asthma, inhaled corticosteroids reduce exacerbations, hospitalisations and mortality, and confidence in this is high. Reliever-only (short-acting beta-agonist) treatment is no longer recommended even in mild asthma, because it is associated with severe exacerbations and death — a genuine reversal of decades of practice. In COPD the indication is much narrower: inhaled steroids benefit patients who continue to exacerbate despite bronchodilators, particularly those with higher blood eosinophil counts, and they increase pneumonia risk. Local side effects are common and preventable; systemic effects are real but dose-dependent and small at standard doses.
Well-supported by consistent, high-quality evidence.
Biological Role
Corticosteroids suppress airway inflammation — the underlying process in asthma — by acting on gene transcription in airway cells. Delivered by inhalation, the dose reaching the lung is small and systemic exposure is limited, which is the entire point of the delivery route.
Human Evidence
Extensive. Decades of randomised trials, large outcome trials, and guideline development. This is one of the best-evidenced treatments in respiratory medicine.
Clinical Benefit
In asthma: fewer exacerbations, fewer admissions, fewer deaths. In COPD: fewer exacerbations in a defined subgroup, and a mortality signal from triple therapy.
Broader Claims
Inhaled steroids do not benefit everyone with COPD, and they are not a treatment for a cough or a cold. The idea that they are interchangeable with the anabolic steroids used in sport is simply a confusion of names.
Safety Confidence
Well characterised, and honestly mixed: local effects (thrush, hoarse voice) are common and largely preventable; systemic effects are dose-dependent; and in COPD there is a real increase in pneumonia risk.
Research Activity
Very active — reliever-based regimens, eosinophil-guided therapy in COPD, and biologics for severe asthma have all changed practice recently.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
9/9
steps proven in humans
Evidence-rich
Proven at every applicable step — rare, and worth noticing.
Guideline / regulatory support
ProvenRecommended as cornerstone therapy for asthma at all severities. Reliever-only treatment explicitly no longer recommended. Eosinophil-guided use in COPD.
Clinical outcomes
ProvenReduced exacerbations, hospital admissions and asthma deaths. In COPD, reduced exacerbations in a defined subgroup with a mortality signal from triple therapy. This rung is why the record exists.
Large human RCTs
ProvenIncluding trials of as-needed inhaled-steroid reliever regimens and of triple therapy in COPD.
Small human outcome trials
ProvenNumerous.
Human safety data
ProvenExtensive. Local effects common and preventable; systemic effects dose-dependent; pneumonia risk in COPD established.
Human biomarker / pharmacology
ProvenAirway inflammation, exhaled nitric oxide and eosinophil counts all respond measurably. Lung deposition and systemic bioavailability are well described.
Animal
ProvenSubstantial.
Cell / in vitro
ProvenGlucocorticoid receptor signalling and its effects on inflammatory gene transcription are extensively characterised.
Mechanistic plausibility
ProvenCorticosteroids suppress the airway inflammation that is the underlying disease in asthma. Well established.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
What We Know
Inhaled corticosteroids reduce asthma exacerbations, hospital admissions and deaths. Reliever-only treatment is associated with severe attacks and mortality, and is no longer recommended even in mild asthma. In COPD, benefit is confined to a subgroup and pneumonia risk rises.
What We Think
The central problem in asthma is not that we lack an effective drug — it is that the effective drug feels like it does nothing, while the ineffective one works within seconds. That asymmetry, not ignorance, is what drives reliever over-reliance. Any honest account of this treatment has to start there.
What We Don't Know
Exactly how to identify which COPD patients gain most, beyond the blood eosinophil count. The long-term consequences of decades of standard-dose inhaled steroid use in children are reassuring but not fully settled.
Active Research
Anti-inflammatory reliever regimens (inhaled steroid combined with a fast-acting bronchodilator, used as needed) have moved rapidly into guidelines. Eosinophil-guided therapy in COPD and biologics for severe asthma are both active and genuinely changing outcomes.
What Could Change Our Mind
A clear demonstration of unexpected long-term systemic harm at standard doses would alter the risk-benefit. Nothing plausible threatens the core asthma finding — it is among the sturdiest results in respiratory medicine.
The biggest myth
“You only need an inhaler when you have symptoms”
This is the belief that kills people, and it deserves to be stated that starkly. Asthma is a disease of ongoing airway inflammation that is present between attacks, when you feel completely fine. Treating only the symptom — reaching for the reliever when you cannot breathe — leaves the inflammation untouched and the airway primed for the next, worse attack. Reviews of asthma deaths repeatedly find the same pattern: heavy reliever use, and preventer inhalers left unused or unfilled. Guidelines now recommend that essentially everyone with asthma, including mild asthma, receives inhaled-steroid-containing therapy, and that reliever-only treatment be abandoned.
Ask BioSignal
Still have a question about inhaled corticosteroids?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take inhaled corticosteroids
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
Almost nobody searches for 'inhaled corticosteroids'. They search for whether their brown inhaler is dangerous, whether they can stop taking it now they feel fine, and whether it is the same as the steroids they have read about in sport. That gap — between the clinical name and the question people actually have — is why this record matters. The interest is anxious rather than aspirational: this is not a product anyone wants to take, it is one they have been told to take and privately suspect they may not need. Which is precisely the psychology that leads people to lean on the reliever, feel fine, and then have the attack that kills them.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
FDA-approved. Prescription only
Availability
Prescription only — clinician-directed
Sport (WADA)
Inhaled corticosteroids are permitted (inhaled beta-2 agonists have separate restrictions — check the current list)
Known safety profile
Well characterised, and genuinely two-sided. Local effects are common and largely preventable. Systemic effects are dose-dependent and small at standard doses. In COPD there is a real increase in pneumonia risk, which is precisely why the indication there is narrow rather than universal. BioSignal states the risks plainly, because a safety message that oversells reassurance will not be believed by the people who most need to hear the efficacy one.
Common issues
- Oral thrush (candidiasis) — largely preventable with a spacer and by rinsing the mouth after use
- Hoarse voice (dysphonia)
- Sore throat and cough on inhalation
- In COPD: increased risk of pneumonia — a genuine harm, not a footnote
Use caution if
- Children — modest reduction in growth velocity; use the lowest effective dose and review regularly. Do NOT stop out of fear
- People on high doses long term — adrenal suppression, reduced bone density, cataracts and glaucoma become relevant
- People with COPD and low blood eosinophils — limited benefit, and pneumonia risk remains
- Anyone with recurrent pneumonia on inhaled steroids for COPD — the balance should be reconsidered
- Anyone not using a spacer, or with poor inhaler technique — the drug may not be reaching the lung at all
Long-term unknowns
The long-term systemic consequences of standard-dose inhaled steroid use begun in early childhood and continued for decades are reassuring in the data available, but not fully settled. High-dose long-term use is a different risk category from standard-dose use, and the two should not be discussed as if they were the same.
Limits of this evidence
The efficacy evidence in asthma is strong and does not require hedging. The genuine uncertainties sit elsewhere: precisely which COPD patients benefit, when inhaled steroids can be safely withdrawn in COPD, and the true long-term systemic effect of decades of standard-dose use started in childhood.
Full regulatory and sport detail
- Regulatory approval
- FDA-approved for asthma, and in combination products for COPD. Prescription only. Available as inhaled steroid alone and in combination with long-acting bronchodilators.
- Approved indication
- Asthma (maintenance); COPD (in combination, for exacerbation reduction in selected patients).
- Research chemical
- N/A — approved medicines.
- Sport (WADA)
- Inhaled corticosteroids are permitted under current anti-doping rules. Confirm against the current list; other inhaled agents are treated differently.
- Publication note
- Guideline positions in this area changed substantially and recently — particularly the abandonment of reliever-only treatment in asthma. Re-confirm current GINA and GOLD positions at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 10 popular claims about inhaled corticosteroids.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 3
- Mixed evidence
- 2
- Not established
- 5
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- Inhaled corticosteroids reduce asthma attacks and deaths
- Inhaled steroids increase pneumonia risk in COPD
- Triple inhaler therapy improves survival in COPD
Mixed evidence
- Long-term steroid inhalers are dangerous
- Steroid inhalers stunt children's growth
Not established
- You only need an inhaler when you have symptoms
- Reliever-only treatment is fine if my asthma is mild
- Steroid inhalers are the same as the steroids bodybuilders take
- Everyone with COPD should be on an inhaled steroid
- Inhaler technique doesn't really matter
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Inhaled corticosteroids reduce asthma attacks and deathsSupportedHigh confidence
Yes — this is one of the most robust findings in respiratory medicine. Inhaled steroids reduce exacerbations, hospital admissions and asthma mortality, and they do so by treating the inflammation that IS the disease rather than the muscle spasm that is its symptom. They are the cornerstone of asthma treatment for exactly this reason.
Reliever-only treatment is fine if my asthma is mildNot establishedHigh confidence
It is not, and this is a genuine reversal of decades of practice that many people — and some clinicians — have not caught up with. People with mild asthma still die of asthma. Short-acting reliever-only treatment is associated with an increased risk of severe exacerbations and death, and major guidelines no longer recommend it at any severity. The modern approach uses an inhaled steroid combined with a fast-acting bronchodilator, taken as needed — so the anti-inflammatory arrives every time the reliever does.
Steroid inhalers are the same as the steroids bodybuilders takeNot establishedHigh confidence
Entirely different drugs that unfortunately share a word. Corticosteroids suppress inflammation; anabolic steroids are synthetic testosterone derivatives used to build muscle. They act on different receptors, do different things, and have nothing meaningful in common beyond the name. This confusion causes real harm, because it makes people frightened of a treatment that is preventing their next asthma attack.
Long-term steroid inhalers are dangerousMixedModerate confidence
The concern is legitimate and it is usually overstated. The dose delivered to the lung is small and systemic absorption is limited at standard doses. Local effects — oral thrush and a hoarse voice — are common and largely preventable by using a spacer and rinsing your mouth. At HIGH doses over long periods, systemic effects do become relevant: adrenal suppression, reduced bone density, cataracts and glaucoma. The honest framing is a comparison, not a reassurance: the risks of standard-dose inhaled steroids are real and small, and the risks of untreated asthma include dying of it.
Steroid inhalers stunt children's growthMixedModerate confidence
There is a real effect and it is small, and parents deserve the actual number rather than reassurance. Inhaled corticosteroids modestly reduce growth velocity in the first year of treatment, and the effect on final adult height is on the order of about a centimetre. That is a genuine cost. It should be weighed against uncontrolled asthma, which impairs sleep, school, exercise and growth in its own right — and can kill. Use the lowest effective dose, and review it. Do not stop the inhaler out of fear.
Everyone with COPD should be on an inhaled steroidNot establishedHigh confidence
No — and this is where BioSignal must resist generalising from asthma. In COPD, inhaled steroids benefit a defined subgroup: people who continue to exacerbate despite bronchodilator therapy, particularly those with higher blood eosinophil counts. In people with low eosinophils and no exacerbations, the benefit is minimal and the pneumonia risk is not. The blood eosinophil count is the marker that guides this decision, and it is one of the more genuinely useful tests in respiratory medicine.
Inhaled steroids increase pneumonia risk in COPDSupportedHigh confidence
Yes, and this is not a small print item — it is the reason the COPD indication is narrow rather than universal. Inhaled corticosteroids increase the risk of pneumonia in COPD. That real harm is why the decision must be targeted at those who will actually benefit, and why 'everyone gets one' would be poor medicine.
Triple inhaler therapy improves survival in COPDSupportedModerate confidence
In appropriately selected patients — those with a history of exacerbations — large trials of triple therapy (inhaled steroid plus two bronchodilators) have shown reduced exacerbations and a mortality signal compared with dual bronchodilator therapy. This matters because COPD is so widely regarded as untreatable. It is not.
Inhaler technique doesn't really matterNot establishedHigh confidence
It matters enormously, and this is the most fixable failure in the whole field. A large proportion of people use their inhaler incorrectly, which means the drug never reaches the airway — the prescription is filled, the patient believes they are treated, and effectively nothing is being delivered. A spacer improves delivery and reduces local side effects. Having your technique checked is free, takes two minutes, and is more valuable than most things people buy for their lungs.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Asthma — all severities (current guideline approach)
- Intervention
- Inhaled corticosteroid-containing therapy
- Dose
- Clinician-determined; lowest effective dose
- Duration
- Ongoing — this is a controller, not a rescue
- Outcome
- Exacerbations, symptom control, lung function
- Notes
- Reliever-only (SABA) treatment is no longer recommended at ANY severity
Asthma — mild
- Intervention
- As-needed inhaled steroid + fast-acting bronchodilator combination
- Dose
- Clinician-determined, taken as needed
- Duration
- As required
- Outcome
- Severe exacerbations
- Notes
- The anti-inflammatory arrives every time the reliever does — the core design idea
COPD — exacerbations despite bronchodilators, higher eosinophils
- Intervention
- Inhaled steroid added to bronchodilator therapy
- Dose
- Clinician-determined
- Duration
- Ongoing, with review
- Outcome
- Exacerbation rate
- Notes
- Blood eosinophil count guides this. Pneumonia risk is the counterweight
COPD — low eosinophils, no exacerbations
- Intervention
- Inhaled steroid
- Dose
- Generally not indicated
- Duration
- N/A
- Outcome
- Minimal benefit; pneumonia risk remains
- Notes
- Withdrawal can be appropriate in selected patients (clinician-directed)
Everyone using one
- Intervention
- Spacer + rinse mouth after use
- Dose
- N/A
- Duration
- Every dose
- Outcome
- Drug delivery; prevention of thrush and dysphonia
- Notes
- The cheapest, most under-used intervention in respiratory medicine
Where scientists agree — and don’t
Agreed
- Inhaled corticosteroids reduce asthma exacerbations, admissions and deaths.
- Reliever-only treatment of asthma is no longer recommended at any severity.
- In COPD, inhaled steroids benefit a subgroup and increase pneumonia risk.
- Blood eosinophil count guides inhaled steroid use in COPD.
- Inhaler technique and adherence are major, under-addressed determinants of outcome.
Debated
- The precise eosinophil threshold that should trigger inhaled steroid therapy in COPD.
- When inhaled steroids can safely be withdrawn in COPD.
- The magnitude and reversibility of growth effects in children.
Unknown
- Long-term systemic consequences of decades of standard-dose use begun in childhood.
- How best to identify COPD responders beyond eosinophil count.
What remains unknown
- Why, despite decades of clear evidence, do so many people with asthma still rely on the reliever alone — and what would actually change that?
- Can we identify COPD patients who will benefit from inhaled steroids more precisely than by eosinophil count?
- What are the true long-term systemic effects of standard-dose inhaled steroids started in early childhood?
Questions people actually ask
Should I use my rescue inhaler every day?
If you are needing your reliever every day, that is not a routine to settle into — it is the single clearest sign that your asthma is not controlled, and it is the pattern found again and again in reviews of people who died of asthma. The reliever relaxes the muscle around the airway. It does nothing whatsoever to the inflammation that is causing the airway to narrow in the first place, so it treats the symptom and leaves the disease. Heavy reliever use is a warning light, not a treatment plan. If this is you, please get reviewed — and expect the answer to involve an inhaled steroid.
Are steroid inhalers safe?
Broadly yes, and the fear is not stupid — it deserves a real answer rather than a pat one. These genuinely are steroids, and the dose that reaches your bloodstream, while small, is not zero. Local side effects are common: oral thrush and a hoarse voice, both largely preventable with a spacer and by rinsing your mouth after each dose. At high doses over long periods, systemic effects become relevant — bone density, adrenal function, cataracts. What makes them safe is not that they are harmless; it is that at standard doses the harms are small and the alternative is uncontrolled asthma, which impairs your life and can end it. The honest answer is not 'don't worry'. It is 'this is a real trade, and it is not a close one'.
Are these the same as the steroids athletes use?
No — and it is worth being emphatic, because this confusion frightens people away from a treatment that is protecting them. Anabolic steroids are testosterone derivatives used to build muscle. Corticosteroids are anti-inflammatory drugs that act on entirely different receptors and do an entirely different job. They share four syllables and nothing else. Your preventer inhaler will not build muscle, will not affect your hormones at standard doses, and is not the thing you have read about in sport.
My child has been prescribed a steroid inhaler. Will it stunt their growth?
There is a small real effect, and you deserve the number rather than a reassurance. Inhaled corticosteroids slightly slow growth in the first year of treatment, and the effect on final adult height is on the order of about a centimetre. That is a genuine cost and it is right to weigh it. Weigh it against this: uncontrolled asthma disturbs sleep, keeps children off school and off the sports field, impairs growth in its own right, and kills children every year. Use the lowest effective dose, have it reviewed regularly, and use a spacer. The one thing not to do is stop it out of fear.
I have COPD — should I be on one?
Maybe, and unlike in asthma the honest answer is genuinely 'it depends'. Inhaled steroids help people with COPD who keep having exacerbations despite bronchodilator inhalers, and they help most in those with a higher blood eosinophil count — a simple blood test that is one of the more useful things in respiratory medicine. If your eosinophils are low and you are not exacerbating, the benefit is small and the pneumonia risk — which is real — is not worth it. This is a conversation with your clinician, and 'everyone with COPD should have one' is not the right answer.
Practical takeaways
- The preventer is the one that saves your life. The reliever is the one that feels like it does.
- Reliever-only treatment of asthma is no longer recommended — at any severity, including mild.
- These are not the steroids used in sport. Different drugs, different receptors, same unfortunate word.
- The risks are real and dose-dependent — and far smaller than the risk of untreated asthma.
- In COPD the indication is narrow: it depends on exacerbations and eosinophils, and it raises pneumonia risk.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
Corticosteroids suppress airway inflammation — the underlying process in asthma — by acting on gene transcription in airway cells. Delivered by inhalation, the dose reaching the lung is small and systemic exposure is limited, which is the entire point of the delivery route.
How we found out
Asthma Reconceived as an Inflammatory Disease
For decades asthma was treated as a problem of bronchial muscle spasm, and the treatment was a bronchodilator. The recognition that the underlying disease is chronic airway INFLAMMATION reframed everything: the muscle spasm was the symptom, not the disease.
Inhaled Steroids Become the Cornerstone
Delivering corticosteroid directly to the airway allowed the inflammation to be treated with a small dose and limited systemic exposure. Exacerbations, admissions and deaths fell, and inhaled steroids became the foundation of asthma care.
The Reliever Problem
Reviews of asthma deaths found the same pattern repeatedly: heavy reliever use, and preventer inhalers unfilled or unused. The drug that worked instantly was crowding out the drug that was keeping people alive — not through ignorance, but through the plain psychology of relief.
The Reversal
Guidelines abandoned reliever-only treatment at every severity, including mild asthma, and moved to regimens in which an inhaled steroid is combined with a fast-acting bronchodilator — so the anti-inflammatory arrives every time the reliever does.
COPD Is Not Asthma
Attempts to generalise inhaled steroids to all of COPD ran into two findings: benefit is confined largely to those who exacerbate, and concentrated in those with higher blood eosinophils — and pneumonia risk rises. The eosinophil count became a practical guide to who should actually receive one.
References
Verified sources. BioSignal does not print a citation it has not checked.
References for this record are being verified and will be published with the next review. BioSignal does not print citations it has not checked.
Version history
Version 1.0
Initial record (Editorial Expansion, Batch 9). Authored directly to the Signal Record v2 publishing standard. Written because the Respiratory hub had the thinnest record shelf in the graph — three records, none of which treated a respiratory disease — while the most effective controller therapy in respiratory medicine had no page. Calibration: Established maturity, HIGH confidence in asthma efficacy and in the abandonment of reliever-only treatment; moderate confidence in the magnitude of growth effects and in the COPD mortality signal. The record deliberately does NOT minimise steroid fear: the growth effect is real and quantified, the pneumonia risk in COPD is stated as a genuine harm, and high-dose systemic effects are named. A safety message that oversells reassurance would not be believed by the people who most need to hear the efficacy message. Review cadence: Annually.
Continue exploring
Three places this record leads next.